Emergent BioSolutions Inc. EBS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -443.48% | -226.74% | 93.47% | 127.60% | 136.35% |
| Total Depreciation and Amortization | -10.84% | -7.27% | -11.96% | -12.23% | -9.70% |
| Total Amortization of Deferred Charges | -19.15% | 4,150.00% | 232.14% | 32.43% | -13.76% |
| Total Other Non-Cash Items | 1,314.47% | 853.85% | -89.66% | -21.60% | -59.64% |
| Change in Net Operating Assets | 172.64% | -77.75% | -34.07% | -125.25% | -187.50% |
| Cash from Operations | 1,439.23% | -42.19% | 34.42% | 190.63% | -92.38% |
| Capital Expenditure | -0.86% | 15.71% | 19.75% | 39.74% | 64.42% |
| Sale of Property, Plant, and Equipment | -85.45% | -99.57% | -99.78% | 383.54% | 406.58% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -100.00% |
| Other Investing Activities | -163.87% | -167.20% | -63.64% | 50.00% | -- |
| Cash from Investing | -152.99% | -128.53% | -96.16% | -44.57% | 19.60% |
| Total Debt Issued | -- | -33.56% | -- | -- | -100.00% |
| Total Debt Repaid | -4,597.10% | 36.44% | 76.24% | 76.68% | 98.62% |
| Issuance of Common Stock | 50.00% | -74.31% | -77.06% | -79.63% | -83.18% |
| Repurchase of Common Stock | -81.29% | -386.59% | -2,792.31% | -2,091.67% | -1,610.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -344.68% | -- | -- | 100.00% |
| Cash from Financing | -883.78% | 11.25% | 36.13% | 28.11% | 88.05% |
| Foreign Exchange rate Adjustments | -100.00% | -166.67% | 214.29% | -- | 106.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.91% | -165.05% | -88.21% | 1,796.72% | 35.28% |